

EMA/339337/2023

European Medicines Agency decision P/0293/2023

of 4 August 2023

on the refusal of a paediatric investigation plan and on the granting of a waiver for volrustomig (EMA-003423-PIP01-23) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0293/2023

of 4 August 2023

on the refusal of a paediatric investigation plan and on the granting of a waiver for volrustomig (EMA-003423-PIP01-23) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency²,

Having regard to the application submitted by AstraZeneca AB on 20 March 2023 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 23 June 2023, in accordance with Article 17 of Regulation (EC) No 1901/2006 and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the refusal of a paediatric investigation plan and on the granting of a waiver.
- (2) It is therefore appropriate to adopt a decision refusing a paediatric investigation plan.
- (3) It is therefore appropriate to adopt a decision granting a waiver.

¹ OJ L 378, 27.12.2006, p.1, as amended.

² OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

A paediatric investigation plan for volrustomig, concentrate for solution for injection/infusion, intravenous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby refused.

Article 2

A product-specific waiver for volrustomig, concentrate for solution for injection/infusion, intravenous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

This decision is addressed to AstraZeneca AB, Södertälje, SE-151-85 - Södertälje, Sweden.

EMA/PDCO/248013/2023
Amsterdam, 23 June 2023

Opinion of the Paediatric Committee on the refusal of a Paediatric Investigation Plan and on the granting of a product-specific waiver

EMA-003423-PIP01-23

Scope of the application

Active substance(s):

Volrustomig

Invented name and authorisation status:

See Annex II

Condition(s):

Treatment of cervical cancer

Treatment of lung cancer

Treatment of mesothelioma

Treatment of renal cell carcinoma

Pharmaceutical form(s):

Concentrate for solution for injection/infusion

Route(s) of administration:

Intravenous use

Name/corporate name of the PIP applicant:

AstraZeneca AB

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, AstraZeneca AB submitted for agreement to the European Medicines Agency on 20 March 2023 an application for a paediatric investigation plan for the above mentioned medicinal product and a waiver under Article 13 of said Regulation.

The procedure started on 24 April 2023.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to refuse the paediatric investigation plan in accordance with Article 17(1) of said Regulation as the measures and the timelines are not appropriate to ensure the generation of the necessary data determining the conditions in which the medicinal product may be used to treat the paediatric population or some subsets, nor to adapt a paediatric formulation, or do not bring expected significant therapeutic benefit;
 - to grant a product-specific waiver for all subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(b) of said Regulation, on the grounds that the disease or condition for which the specific medicinal product is intended occurs only in adult populations and does not occur in the specified subset(s) of the paediatric population and Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The grounds for the granting of the waiver are set out in Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

Grounds for the granting of the waiver

1. Waiver

1.1. Condition:

Treatment of cervical cancer

The waiver applies to:

- The paediatric population of male patients from birth to less than 18 years of age and female patients from birth to less than 14 years of age;
 - for concentrate for solution for injection/infusion, intravenous use;
 - on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).
- and
- the paediatric population of female patients from 14 years of age to less than 18 years of age;
 - for concentrate for solution for injection/infusion, intravenous use;
 - on the grounds that clinical studies with the specific medicinal product cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the specified paediatric subset(s).

1.2. Condition:

Treatment of lung cancer

The waiver applies to:

- The paediatric population from birth to less than 18 years of age;
- concentrate for solution for injection/infusion, intravenous use;
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).

1.3. Condition:

Treatment of mesothelioma

The waiver applies to:

- The paediatric population from birth to less than 18 years of age;
- concentrate for solution for injection/infusion, intravenous use;
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).

1.4. Condition:

Treatment of renal cell carcinoma

The waiver applies to:

- The paediatric population from birth to less than 18 years of age;

- concentrate for solution for injection/infusion, intravenous use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies are not feasible.

Annex II

Information about the authorised medicinal product

Information provided by the applicant:

The product is not authorised anywhere in the European Community.